Translate page

× To share and enhance best practice management of CML, experts and interested clinicians can discuss difficult or interesting CML cases here. Physicians submit a brief history of the patient and the case for discussion (no more than 200 words) by posting it in this forum ("New Discussion" button below). Please include the country of origin.

Each clinical case will be forwarded to the expert clinical panel for a brief independent response. Consideration should be given to patient confidentiality. Details that are not critical to the case can be changed to preserve anonymity. Please consider including your email with the case. This will not be posted on the website, but is useful should further details be requested by the moderator.

As a full clinical history is necessary for accurate comment, cases and comments on the Forum are ONLY ACCEPTED FROM PHYSICIANS. If individual patients have a specific question we encourage them to contact their healthcare provider. General questions can be emailed to info@cml-foundation.org.

DISCLAIMER: The iCMLf does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this Forum is solely at your own risk.

A 19 yo on asciminib as 4L, new updates

  • Nobuko Hijiya
  • Nobuko Hijiya's Avatar Topic Author
7 months 2 weeks ago - 7 months 4 days ago #1930 by Nobuko Hijiya
A 19 yo on asciminib as 4L was created by Nobuko Hijiya
The patient is a 19 yo male.  He was initially diagnosed in 2017.  He came to us from another center after he failed imatinib, dasatinib and nilotinib.    There is no doubt about his compliance.    He has responded to each TKI initially, then, the level went up.   He did not have TKD mutations.   When he was referred to our BMT team, I suggested asciminib as he was18 yo. (Asciminib has not been approved for children.)  He started standard dose 40 mg BID in April 2022 and achieved molecular remission.   He achieved MR3 in 4 months but there are some up and downs up to 0.5%4/12/22       10.3% (prior to asciminib)5/31/22       3.4%8/19/22       0.13%11/18/22     0.039% (MR3)3/9/23         0.065%6/27/23       0.58% (lost MR3)7/10/23       0.375%7/28/23       0.098% (regained MR3)8/29/23      0.028%  (the lowest so far)9/25/23      0.108%10/25/23    0.21%The best donor option is haplo.   What do you recommend?
I appreciate your thoughts.  
Nobuko

Nobuko Hijiya, MD
Pediatric Oncology
Columbia University Irving Medical Center
Last edit: 7 months 4 days ago by arlene.
  • Delphine Rea
  • Delphine Rea's Avatar Topic Author
7 months 4 days ago - 7 months 4 days ago #1932 by Delphine Rea
Replied by Delphine Rea on topic A 19 yo on asciminib as 4L
Dear Nobuko,

I suggest to maintain him on asciminb, simplify at 80mg QD and from time to time if fluctuation stable, ask for KD mutation analysis.

Best regards,

Delphine Rea
Last edit: 7 months 4 days ago by arlene.
  • Tim Hughes
  • Tim Hughes's Avatar Topic Author
7 months 4 days ago - 7 months 4 days ago #1933 by Tim Hughes
Replied by Tim Hughes on topic A 19 yo on asciminib as 4L
Hi Nobuko,

Very difficult case. It looks like he will not sustain a good molecular response to asciminib but I would probably watch for a few more months to be sure. If he is losing response to asciminib, which looks likely, and given the less than ideal donor, I would be thinking about ponatinib (45 mg/day with reduction to 15mg/day if/when he achieves MR2) as a last chance before considering the transplant option. Before stopping the asciminib it would be important to screen for kinase domain and myristoyl site mutations. Any single mutation should not represent a problem for ponatinib but if he has compound mutations, ponatinib may not be a good option – depending on the actual mutations.

Cheers - Tim
Last edit: 7 months 4 days ago by arlene.
  • Nobuko Hijiya
  • Nobuko Hijiya's Avatar Topic Author
1 month 4 days ago - 1 month 4 days ago #1951 by Nobuko Hijiya
Replied by Nobuko Hijiya on topic A 19 yo on asciminib as 4L, new updates
Hi.
I want to have your thoughts on the same case we discussed a while ago. The patient is now 20 yo. He has failed with three TKIs, started asciminib in Apr 2022, and maintained the PCR in 0.1-0.2%IS range but attained MMR only a few times. I previously said he was on 40 mg BID, but actually, he was on 80 mg QD.
He came back for follow up recently and PCR went up to 2%. I asked our BMT team to do donor search again and now, they have an unrelated donor with 9/10 match. (Previously, there was only haplo.) I have thought about switching asciminib to ponatinib, but I think the same thing will likely happen; he will respond, but will lose molecular remission after a while.

With a better donor option, I am thinking about taking him to HSCT now.
I would appreciate your suggestions

Nobuko Hijiya
Columbia University, NYC
Last edit: 1 month 4 days ago by arlene.
  • Jeffrey Lipton
  • Jeffrey Lipton's Avatar Topic Author
1 month 3 days ago #1952 by Jeffrey Lipton
Replied by Jeffrey Lipton on topic A 19 yo on asciminib as 4L
there is little data on PON after ASC, but even with a response, I would not be confident about durability
I would allograft ASAP before he blasts off
  • Michael Mauro
  • Michael Mauro's Avatar Topic Author
1 month 2 days ago #1953 by Michael Mauro
Replied by Michael Mauro on topic A 19 yo on asciminib as 4L
HI Nobuko
Tough case
I would re-screen for ABL kinase mutations as this could explain the failure to asciminib.
Unless there are barriers to treatment or concern over specific AEs ponatinib would be reasonable at 45 mg to start to try to salvage but this then raises the SCT agenda higher as longer term ponatinib may carry greater risk. As Jeff mentioned we don't have much sense with the sequential response estimate but i do agree with the approach of 'lower risk, possibly higher yield' asciminib first...
Best
Mike
Moderators: Nicolaarlene